Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma
Go back to Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma| Pfizer Inc. (NYSE: PFE) | Delayed: 27.59 -0.06 (0.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.65 | 52 Week High | $37.39 | |||
| Open | $27.80 | 52 Week Low | $28.25 | |||
| Day High | $27.85 | P/E | 16.72 | |||
| Day Low | $27.42 | EPS | $1.65 | |||
| Volume | 14,580,648 | |||||
